THE WOODLANDS, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will present data from two studies related to LX9851, its investigational ...
MED Institute, a leader in pre-clinical and clinical medical product development services, is proud to announce a strategic collaboration with Sus Clinicals, a pioneering provider of genetic-modified ...
Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025 Preclinical Data Highlight: Antigen specific immune ...
Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.
The Swiss healthtech startup’s patented multi-tissue platform is designed to improve the speed, safety, and human relevance ...
Pfizer Inc. has presented preclinical data on its first-in-class, selective cyclin-dependent kinase 4 (CDK4) inhibitor compound, PF-07220060, that has shown 20-fold and 4-fold increased selectivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback